Take­da’s gene edit­ing part­ner is snapped up for $250M cash as sec­tor con­tin­ues to heat up

Look­ing to make genome edit­ing its “fourth pil­lar” of op­er­a­tions, Japan’s AnGes is buy­ing out Take­da-part­nered Emen­do­Bio for $250 mil­lion — and with it, tech­nol­o­gy de­signed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER